ArticleTaiwan journal of ophthalmology
Subcutaneous golimumab in the treatment of Juvenile idiopathic arthritis-associated anterior uveitis after failing other tumor necrosis factor alpha inhibitors.
Article in Taiwan journal of ophthalmology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate the efficacy and safety of subcutaneous (SQ) golimumab (GLM) in patients with juvenile idiopathic arthritis (JIA)-associated anterior uveitis who failed prior tumor necrosis factor alpha (TNF-α) inhibitors. MATERIALS AND
methodsThis retrospective case series included 16 eyes from 8 patients with JIA associated anterior uveitis who had previously failed at least one TNF-α inhibitor. Data collected included demographics, previous treatments, best-corrected visual acuity (BCVA), and uveitis severity. Assessments were made at baseline, and at 3, 6, and 12 months following SQ GLM initiation.
resultsEight patients (87.5% female, all white) with an average age of 18.6 years were included. Uveitis was bilateral and chronic in all cases. Five patients (62.5%) achieved remission after SQ GLM. The average logarithm of the minimum angle of resolution improved significantly from 0.11 at baseline before starting treatment to 0.03 at 12 months after starting treatment (
conclusionSQ GLM shows promise in treating JIA associated anterior uveitis, especially in cases without severe complications. Significant improvement in BCVA and inflammation control suggests its potential as a treatment option, although further studies with larger populations are needed to confirm these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.